Literature DB >> 27150801

Ga-68 DOTATOC PET/CT-Guided Biopsy and Cryoablation with Autoradiography of Biopsy Specimen for Treatment of Tumor-Induced Osteomalacia.

Majid Maybody1, Ravinder K Grewal2, John H Healey3, Cristina R Antonescu4, Louise Fanchon5, Sinchun Hwang6, Jorge A Carrasquillo2, Assen Kirov5, Azeez Farooki7.   

Abstract

Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome caused by small benign tumors of mesenchymal origin also known as phosphaturic mesenchymal tumors mixed connective tissue variant. Excellent prognosis is expected with eradication of the culprit tumor. These small tumors are notoriously difficult to localize with conventional imaging studies; this often leads to an extensive work up and prolonged morbidity. We report a patient with clinical diagnosis of TIO whose culprit tumor was localized with Ga-68 DOTATOC PET/CT and MRI. Biopsy and cryoablation were performed under Ga-68 DOTATOC PET/CT guidance. Autoradiography of the biopsy specimen was performed and showed in situ correlation between Ga-68 DOTATOC uptake and histopathology with millimeter resolution.

Entities:  

Keywords:  Cryoablation; DOTATOC PET/CT; Osteomalacia; Tumor-induced

Mesh:

Substances:

Year:  2016        PMID: 27150801      PMCID: PMC5483397          DOI: 10.1007/s00270-016-1350-1

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  15 in total

1.  Tumor-induced osteomalacia.

Authors:  Suzanne M Jan de Beur
Journal:  JAMA       Date:  2005-09-14       Impact factor: 56.272

2.  Radiofrequency ablation of a tumor causing oncogenic osteomalacia.

Authors:  Eric Hesse; Herbert Rosenthal; Leonard Bastian
Journal:  N Engl J Med       Date:  2007-07-26       Impact factor: 91.245

Review 3.  Tumor-Induced Osteomalacia: an Up-to-Date Review.

Authors:  Anke H Hautmann; Matthias G Hautmann; Oliver Kölbl; Wolfgang Herr; Martin Fleck
Journal:  Curr Rheumatol Rep       Date:  2015-06       Impact factor: 4.592

4.  Clinical long-term outcome, technical success, and cost analysis of radiofrequency ablation for the treatment of osteoblastomas and spinal osteoid osteomas in comparison to open surgical resection.

Authors:  Marc-André Weber; Simon David Sprengel; Georg W Omlor; Burkhard Lehner; Bernd Wiedenhöfer; Hans-Ulrich Kauczor; Christoph Rehnitz
Journal:  Skeletal Radiol       Date:  2015-04-25       Impact factor: 2.199

5.  Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia.

Authors:  Kanhaiyalal Agrawal; Sanjay Bhadada; Bhagwant Rai Mittal; Jaya Shukla; Ashwani Sood; Anish Bhattacharya; Anil Bhansali
Journal:  Clin Nucl Med       Date:  2015-01       Impact factor: 7.794

6.  Successful treatment of tumor-induced osteomalacia with CT-guided percutaneous ethanol and cryoablation.

Authors:  Sean Tutton; Erik Olson; David King; Joseph L Shaker
Journal:  J Clin Endocrinol Metab       Date:  2012-07-26       Impact factor: 5.958

7.  Clinical impact of somatostatin receptor scintigraphy in the management of tumor-induced osteomalacia.

Authors:  Michèle Duet; Samar Kerkeni; Raja Sfar; Cécile Bazille; Frédéric Lioté; Philippe Orcel
Journal:  Clin Nucl Med       Date:  2008-11       Impact factor: 7.794

8.  Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).

Authors:  Michelle Houang; Adele Clarkson; Loretta Sioson; Marianne S Elston; Roderick J Clifton-Bligh; Michael Dray; Dominique Ranchere-Vince; Anne-Valerie Decouvelaere; Arnaud de la Fouchardiere; Anthony J Gill
Journal:  Hum Pathol       Date:  2013-09-20       Impact factor: 3.466

9.  Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature.

Authors:  Andrew L Folpe; Julie C Fanburg-Smith; Steven D Billings; Michele Bisceglia; Franco Bertoni; Justin Y Cho; Michael J Econs; Carrie Y Inwards; Suzanne M Jan de Beur; Thomas Mentzel; Elizabeth Montgomery; Michal Michal; Markku Miettinen; Stacey E Mills; John D Reith; John X O'Connell; Andrew E Rosenberg; Brian P Rubin; Donald E Sweet; Tuyethoa N Vinh; Lester E Wold; Brett M Wehrli; Kenneth E White; Richard J Zaino; Sharon W Weiss
Journal:  Am J Surg Pathol       Date:  2004-01       Impact factor: 6.394

10.  Tumor-Induced Osteomalacia: Increased Level of FGF-23 in a Patient with a Phosphaturic Mesenchymal Tumor at the Tibia Expressing Periostin.

Authors:  Anke H Hautmann; Josef Schroeder; Peter Wild; Matthias G Hautmann; Elisabeth Huber; Patrick Hoffstetter; Martin Fleck; Christiane Girlich
Journal:  Case Rep Endocrinol       Date:  2014-08-24
View more
  7 in total

1.  Multimodality Image-Guided Cryoablation for Inoperable Tumor-Induced Osteomalacia.

Authors:  Sri Harsha Tella; Hayet Amalou; Bradford J Wood; Richard Chang; Clara C Chen; Cemre Robinson; Michelle Millwood; Lori C Guthrie; Sheng Xu; Elliot Levy; Venkatesh Krishnasamy; Rachel I Gafni; Michael T Collins
Journal:  J Bone Miner Res       Date:  2017-09-06       Impact factor: 6.741

Review 2.  PET Molecular Imaging-Directed Biopsy: A Review.

Authors:  Baowei Fei; David M Schuster
Journal:  AJR Am J Roentgenol       Date:  2017-05-15       Impact factor: 3.959

3.  Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours.

Authors:  Marie Paquet; Mathieu Gauthé; Jules Zhang Yin; Valérie Nataf; Ophélie Bélissant; Philippe Orcel; Christian Roux; Jean-Noël Talbot; Françoise Montravers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-03-12       Impact factor: 9.236

Review 4.  New Therapies for Hypophosphatemia-Related to FGF23 Excess.

Authors:  Diana Athonvarangkul; Karl L Insogna
Journal:  Calcif Tissue Int       Date:  2020-06-05       Impact factor: 4.333

5.  Effective localization in tumor-induced osteomalacia using 68Ga-DOTATOC-PET/CT, venous sampling and 3T-MRI.

Authors:  Shintaro Kawai; Hiroyuki Ariyasu; Yasushi Furukawa; Reika Yamamoto; Shinsuke Uraki; Ken Takeshima; Kenji Warigaya; Yuji Nakamoto; Takashi Akamizu
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2017-04-19

Review 6.  Clinical Applications of Somatostatin Receptor (Agonist) PET Tracers beyond Neuroendocrine Tumors.

Authors:  Rasmus Helgebostad; Mona-Elisabeth Revheim; Kjersti Johnsrud; Kristine Amlie; Abass Alavi; James Patrick Connelly
Journal:  Diagnostics (Basel)       Date:  2022-02-18

Review 7.  Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation.

Authors:  Kijung Kwak; Bo Yu; Robert J Lewandowski; Dong-Hyun Kim
Journal:  Theranostics       Date:  2022-02-14       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.